PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10421452-8 1999 An enzyme exhibiting both ChE-like substrate specificity and relative resistance to mipafox inhibition (k2/mipafox = 5.2 (+/- 1.0) x 10(-1)) was classified as atypical cholinesterase. mipafox 84-91 RBPJ pseudogene 3 Homo sapiens 104-120 12791540-0 2003 Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase. mipafox 82-89 patatin like phospholipase domain containing 6 Gallus gallus 122-148 12746135-5 2003 The I50 (20 min at 37 degrees C) for N,N"-di-2-propylphosphorodiamidofluoridate (mipafox) against hen lymphocyte NTE was 6.94 +/- 0.28 microM amperometrically and 6.02 +/- 0.71 microM colorimetrically. mipafox 81-88 patatin like phospholipase domain containing 6 Homo sapiens 113-116 11180931-4 2001 The specificity of NTE in blood for mipafox and di-2-propyl phosphorofluoridate was close to that for neuronal NTE. mipafox 36-43 patatin like phospholipase domain containing 6 Homo sapiens 19-22 10720708-5 2000 NTE is defined as the activity resistant to paraoxon (40 microM) and sensitive to mipafox (50 microM). mipafox 82-89 patatin like phospholipase domain containing 6 Homo sapiens 0-3 10421491-11 1999 The target of promotion of axonopathies is thought to be similar or linked to NTE which is defined as the phenyl valerate esterase activity (PVE) in nervous tissues resistant to paraoxon and sensitive to mipafox (40 and 50 microM, pH 8.0, 20 min, respectively). mipafox 204-211 patatin like phospholipase domain containing 6 Homo sapiens 78-81 10421492-9 1999 Under this improved sequential paraoxon/mipafox inhibition procedure S-NTE represents about 50% of total PVases while in the usual concurrent assay it was only apparently about 1-2%. mipafox 40-47 patatin like phospholipase domain containing 6 Homo sapiens 71-74 12769600-9 2002 It is now known that this other site is similar to NTE in that it is also sensitive to mipafox but at much higher concentrations. mipafox 87-94 patatin like phospholipase domain containing 6 Gallus gallus 51-54 10421495-4 1999 The validity of this biosensor method is confirmed by the facts that the calibration curves for NTE obtained by colorimetric and flow-through electrochemical methods were nearly identical and the titration of NTE by test inhibitor mipafox was shown to yield the same pI50 values. mipafox 231-238 patatin like phospholipase domain containing 6 Homo sapiens 96-99 10421495-4 1999 The validity of this biosensor method is confirmed by the facts that the calibration curves for NTE obtained by colorimetric and flow-through electrochemical methods were nearly identical and the titration of NTE by test inhibitor mipafox was shown to yield the same pI50 values. mipafox 231-238 patatin like phospholipase domain containing 6 Homo sapiens 209-212 10421452-8 1999 An enzyme exhibiting both ChE-like substrate specificity and relative resistance to mipafox inhibition (k2/mipafox = 5.2 (+/- 1.0) x 10(-1)) was classified as atypical cholinesterase. mipafox 84-91 butyrylcholinesterase Homo sapiens 168-182 9788582-2 1998 The direct-acting NTE inhibitors block process outgrowth by 50% or more at 50-100 microM for OBDPO and 100-200 microM for mipafox, well below their cytotoxic levels (EC50 values, 445-474 microM for OBDPO and 1021-1613 microM for mipafox). mipafox 122-129 patatin-like phospholipase domain containing 6 Rattus norvegicus 18-21 9788582-2 1998 The direct-acting NTE inhibitors block process outgrowth by 50% or more at 50-100 microM for OBDPO and 100-200 microM for mipafox, well below their cytotoxic levels (EC50 values, 445-474 microM for OBDPO and 1021-1613 microM for mipafox). mipafox 229-236 patatin-like phospholipase domain containing 6 Rattus norvegicus 18-21 9788582-4 1998 These findings suggest that inhibition of neurite-like and cell process outgrowth by OBDPO and mipafox may be associated with NTE inhibition. mipafox 95-102 patatin-like phospholipase domain containing 6 Rattus norvegicus 126-129 9268605-6 1997 For example, apparent IC50 values for NTE inhibition were less than 9.6-fold the apparent IC50 values for AChE inhibition when cells were exposed to the neuropathy-inducing OPs diisopropyl phosphorofluoridate, cyclic tolyl saligenin phosphate, phenyl saligenin phosphate, mipafox, dibutyl dichlorovinyl phosphate, and di-octyl-dichlorovinyl phosphate. mipafox 272-279 patatin like phospholipase domain containing 6 Homo sapiens 38-41 9653066-7 1998 Acetylcholinesterase activity was inhibited by mipafox (65% in the soleus; 76% in the EDL) and ecothiopate (59% in the soleus; 42% in the EDL). mipafox 47-54 acetylcholinesterase Mus musculus 0-20 9586870-2 1998 Dichlorvos administration significantly decreased the activities of neuropathy target esterase and other carboxylesterase viz., paraoxon resistant and mipafox and paraoxon resistant esterases. mipafox 151-158 patatin-like phospholipase domain containing 6 Rattus norvegicus 68-94 9413546-2 1997 The esterase activity in particulate forms, resistant to paraoxon and sensitive to mipafox have been implicated in the initiation of organophosphorus-induced delayed polyneuropathy (OPIDP) and is called neuropathy target esterase (P-NTE). mipafox 83-90 patatin like phospholipase domain containing 6 Gallus gallus 203-229 9413546-2 1997 The esterase activity in particulate forms, resistant to paraoxon and sensitive to mipafox have been implicated in the initiation of organophosphorus-induced delayed polyneuropathy (OPIDP) and is called neuropathy target esterase (P-NTE). mipafox 83-90 patatin like phospholipase domain containing 6 Gallus gallus 233-236 9413546-11 1997 In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively). mipafox 92-99 patatin like phospholipase domain containing 6 Gallus gallus 166-169 9413546-11 1997 In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively). mipafox 92-99 patatin like phospholipase domain containing 6 Gallus gallus 173-176 9413546-11 1997 In all fractions, except brain soluble fractions, within the paraoxon resistant activity, a mipafox sensitive component was detected that is operationally considered NTE (P-NTE and S-NTE in particulate and soluble fractions, respectively). mipafox 92-99 patatin like phospholipase domain containing 6 Gallus gallus 173-176 7991223-6 1994 Marked differences are noted in the duration of cholinergic symptoms and of AChE inhibition after either paraoxon and mipafox, or fenthion poisoning. mipafox 118-125 acetylcholinesterase Rattus norvegicus 76-80 9109545-1 1997 Neuropathy target esterase (NTE) activity is operatively defined in this work as the phenyl valerate esterase (PVase) activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox. mipafox 187-194 patatin like phospholipase domain containing 6 Gallus gallus 0-26 9109545-1 1997 Neuropathy target esterase (NTE) activity is operatively defined in this work as the phenyl valerate esterase (PVase) activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox. mipafox 187-194 patatin like phospholipase domain containing 6 Gallus gallus 28-31 9109545-11 1997 The chromatographic pattern and mipafox sensitivity suggest that the different tissues have a different NTE isoform composition. mipafox 32-39 patatin like phospholipase domain containing 6 Gallus gallus 104-107 9051410-2 1997 Multiple low doses of the direct acting organophosphates, ecothiopate, paraoxon and mipafox produced persistent and additive inhibition of diaphragm acetylcholinesterase. mipafox 84-91 acetylcholinesterase Mus musculus 149-169 9051410-3 1997 Paraoxon and mipafox had similar effects on brain acetylcholinesterase. mipafox 13-20 acetylcholinesterase Mus musculus 50-70 8525498-3 1995 Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively. mipafox 0-7 acetylcholinesterase Mus musculus 45-65 8525498-3 1995 Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively. mipafox 0-7 acetylcholinesterase Mus musculus 67-71 8525498-3 1995 Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively. mipafox 0-7 patatin-like phospholipase domain containing 6 Mus musculus 74-100 8525498-3 1995 Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively. mipafox 0-7 patatin-like phospholipase domain containing 6 Mus musculus 102-105 8525498-3 1995 Mipafox (110 mumol/kg, s.c.) inhibited brain acetylcholinesterase (AChE), neuropathy target esterase (NTE) and phenylvalerate hydrolases by 58, 64 and 65%, while diaphragm AChE and phenylvalerate hydrolases were inhibited by 66 and 80%, respectively. mipafox 0-7 acetylcholinesterase Mus musculus 172-176 8525498-6 1995 Mipafox was a potent inhibitor of AChE and NTE in vitro. mipafox 0-7 acetylcholinesterase Mus musculus 34-38 8525498-6 1995 Mipafox was a potent inhibitor of AChE and NTE in vitro. mipafox 0-7 patatin-like phospholipase domain containing 6 Mus musculus 43-46 7671342-1 1995 Neuropathy target esterase (NTE) activity is operatively defined in this paper as the phenyl valerate esterase activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox. mipafox 180-187 patatin like phospholipase domain containing 6 Gallus gallus 0-26 7671342-1 1995 Neuropathy target esterase (NTE) activity is operatively defined in this paper as the phenyl valerate esterase activity resistant to 40 microM paraoxon but sensitive to 250 microM mipafox. mipafox 180-187 patatin like phospholipase domain containing 6 Gallus gallus 28-31 8568835-2 1995 NTE is operationally defined in this article as the phenylvalerate esterase activity which is resistant to inhibition by 40 microM paraoxon and sensitive to 250 microM mipafox. mipafox 168-175 patatin like phospholipase domain containing 6 Homo sapiens 0-3 8568835-8 1995 However, the inhibition of P-NTE by mipafox, DFP, and HDCP did not show the presence of a considerable proportion of a second component. mipafox 36-43 patatin like phospholipase domain containing 6 Homo sapiens 29-32 8930121-9 1996 The study shows that bovine chromaffin cells possess carboxylesterase activities and respond to inhibition by paraoxon and mipafox, thus facilitating the discrimination of neuropathy target esterase. mipafox 123-130 patatin like phospholipase domain containing 6 Bos taurus 172-198 8812209-1 1996 A method is presented for the isolation of a 155-kDa protein that possesses phenyl valerate hydrolysis activity in the presence of paraoxon but is inhibited by mipafox; the functional definition of neuropathy target esterase (neurotoxic esterase; NTE). mipafox 160-167 patatin like phospholipase domain containing 6 Gallus gallus 198-224 7705869-2 1995 The neurotoxic esterase (NTE) activity was significantly inhibited in the brain, spinal cord and platelets of hens treated with mipafox or sarin whereas no change was noticed with parathion treatment. mipafox 128-135 patatin like phospholipase domain containing 6 Gallus gallus 4-23 7705869-2 1995 The neurotoxic esterase (NTE) activity was significantly inhibited in the brain, spinal cord and platelets of hens treated with mipafox or sarin whereas no change was noticed with parathion treatment. mipafox 128-135 patatin like phospholipase domain containing 6 Gallus gallus 25-28 7983680-3 1994 In the present article, a partial characterization is made of the NTE and other related PV esterases in the bovine adrenal medulla and brain; NTE sensitivity to the neurotoxic organophosphorus compound mipafox is investigated, and its subcellular distribution is studied. mipafox 202-209 patatin like phospholipase domain containing 6 Bos taurus 66-69 7983680-3 1994 In the present article, a partial characterization is made of the NTE and other related PV esterases in the bovine adrenal medulla and brain; NTE sensitivity to the neurotoxic organophosphorus compound mipafox is investigated, and its subcellular distribution is studied. mipafox 202-209 patatin like phospholipase domain containing 6 Bos taurus 142-145 7983680-7 1994 The mipafox inhibition curve of PV esterase activity resistant to 40 microM paraoxon in the particulate fraction of the adrenal medulla suggests that NTE activity fundamentally comprises a mipafox-sensitive component with an I50 of 6.39 microM at 30 minutes, which is similar to the value reported in hen brain. mipafox 4-11 patatin like phospholipase domain containing 6 Bos taurus 150-153 7983680-7 1994 The mipafox inhibition curve of PV esterase activity resistant to 40 microM paraoxon in the particulate fraction of the adrenal medulla suggests that NTE activity fundamentally comprises a mipafox-sensitive component with an I50 of 6.39 microM at 30 minutes, which is similar to the value reported in hen brain. mipafox 189-196 patatin like phospholipase domain containing 6 Bos taurus 150-153 8211998-7 1993 In fact, mipafox and methamidophos as well as certain classic protective inhibitors such as carbamate and sulfonyl fluoride form an inhibited NTE which apparently does not age and yet produces neuropathy. mipafox 9-16 patatin like phospholipase domain containing 6 Homo sapiens 142-145 8140588-0 1994 In vivo inhibition by mipafox of soluble and particulate forms of organophosphorus neuropathy target esterase (NTE) in hen sciatic nerve. mipafox 22-29 patatin like phospholipase domain containing 6 Homo sapiens 83-109 8140588-0 1994 In vivo inhibition by mipafox of soluble and particulate forms of organophosphorus neuropathy target esterase (NTE) in hen sciatic nerve. mipafox 22-29 patatin like phospholipase domain containing 6 Homo sapiens 111-114 8140588-4 1994 In this work we studied the in vivo inhibition of both NTE forms with different doses of mipafox and the results were compared with sensitivity to mipafox in vitro. mipafox 89-96 patatin like phospholipase domain containing 6 Homo sapiens 55-58 7979963-8 1994 Mipafox inhibited brain and diaphragm acetylcholinesterase and brain neuropathy target esterase. mipafox 0-7 acetylcholinesterase Mus musculus 38-58 7979963-8 1994 Mipafox inhibited brain and diaphragm acetylcholinesterase and brain neuropathy target esterase. mipafox 0-7 patatin-like phospholipase domain containing 6 Mus musculus 69-95 8343998-2 1993 We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics. mipafox 126-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-44 8343992-6 1993 It proved difficult to elute active NTE under non-denaturing conditions, but SDS-PAGE analysis of MNTFP-Sepharose bound proteins eluted with 2% SDS identified a 155 kDa NTE-like protein that bound in a trifluoromethylketone- or mipafox-sensitive but paraoxon-insensitive manner. mipafox 228-235 patatin like phospholipase domain containing 6 Gallus gallus 169-172 8337699-0 1993 Modification of mipafox-induced inhibition of neuropathy target esterase in neuroblastoma cells of human origin. mipafox 16-23 patatin like phospholipase domain containing 6 Homo sapiens 46-72 8337699-2 1993 For this study, differentiated SY-5Y cells were treated for up to 10 min with mipafox, an organophosphorus compound, and NTE inhibition was determined when cells exposed to mipafox were also exposed to the carbamate, aldicarb, and to the calcium channel blocker, verapamil. mipafox 173-180 patatin like phospholipase domain containing 6 Homo sapiens 121-124 8337699-4 1993 Less NTE inhibition was observed when either aldicarb or verapamil was included in the incubation of SY-5Y cells with mipafox. mipafox 118-125 patatin like phospholipase domain containing 6 Homo sapiens 5-8 8337699-6 1993 These results indicate that NTE inhibition can be detected in neuroblastoma cells, that these cells respond in a manner similar to chicken brain, and that mipafox-induced inhibition of NTE can be decreased in the presence of aldicarb or verapamil. mipafox 155-162 patatin like phospholipase domain containing 6 Gallus gallus 28-31 8337699-6 1993 These results indicate that NTE inhibition can be detected in neuroblastoma cells, that these cells respond in a manner similar to chicken brain, and that mipafox-induced inhibition of NTE can be decreased in the presence of aldicarb or verapamil. mipafox 155-162 patatin like phospholipase domain containing 6 Gallus gallus 185-188 8343998-2 1993 We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics. mipafox 126-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-50 8343998-2 1993 We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics. mipafox 126-133 patatin like phospholipase domain containing 6 Homo sapiens 56-82 8343998-2 1993 We have found that both acetylcholinesterase (AChE) and neuropathy target esterase (NTE) which had been inhibited with either mipafox or with a di-n-butylphosphorodiamidate could be reactivated by prolonged treatment with aqueous potassium fluoride (KF): the reaction proceeded with first-order kinetics. mipafox 126-133 patatin like phospholipase domain containing 6 Homo sapiens 84-87 8343998-5 1993 We conclude that it is likely that the mipafox-enzyme bond in inhibited NTE and AChE is relatively strong but that aging has not occurred. mipafox 39-46 patatin like phospholipase domain containing 6 Homo sapiens 72-75 8343998-5 1993 We conclude that it is likely that the mipafox-enzyme bond in inhibited NTE and AChE is relatively strong but that aging has not occurred. mipafox 39-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 1471154-2 1992 At doses of 18-182 micrograms mipafox and 9-110 micrograms DFP, inhibition of neuropathy target esterase (NTE) for the treated segment was over 80%, whereas for the adjacent distal and proximal segments inhibition was under 40%, 15 min after application. mipafox 30-37 patatin like phospholipase domain containing 6 Gallus gallus 78-104 1471154-2 1992 At doses of 18-182 micrograms mipafox and 9-110 micrograms DFP, inhibition of neuropathy target esterase (NTE) for the treated segment was over 80%, whereas for the adjacent distal and proximal segments inhibition was under 40%, 15 min after application. mipafox 30-37 patatin like phospholipase domain containing 6 Gallus gallus 106-109 3753463-5 1986 At 25 degrees C, the Km of NTE for phenyl valerate was determined to be about 2.4 X 10(-3) M. Secondly, the kinetic constants of NTE for mipafox were measured at both 25 degrees C and 37 degrees C. With either phenyl valerate or phenyl phenylacetate as substrate, the Km at 37 degrees C was determined to be about 1.8 X 10(-4) M, and the phosphorylation constant (k2) was about 1.1 min-1. mipafox 137-144 patatin like phospholipase domain containing 6 Homo sapiens 129-132 2051750-2 1991 NTE activity is calculated from the rate of phenyl valerate hydrolysis resistant to paraoxon and sensitive to mipafox inhibition under specified conditions of inhibitor concentrations, pH, temperature, and incubation times with inhibitors and substrate. mipafox 110-117 patatin like phospholipase domain containing 6 Homo sapiens 0-3 2703698-1 1989 We developed a histochemical method for localizing neurotoxic esterase (NTE), defined as the phenylvalerate (PV)-hydrolyzing esterase that is resistant to 40 microM paraoxon (A) but inactivated by paraoxon plus 50 microM mipafox (B). mipafox 221-228 patatin like phospholipase domain containing 6 Gallus gallus 51-70 2703698-1 1989 We developed a histochemical method for localizing neurotoxic esterase (NTE), defined as the phenylvalerate (PV)-hydrolyzing esterase that is resistant to 40 microM paraoxon (A) but inactivated by paraoxon plus 50 microM mipafox (B). mipafox 221-228 patatin like phospholipase domain containing 6 Gallus gallus 72-75 3579980-8 1987 Mipafox pI50 values obtained from complete titration curves carried out on NTE solubilized in Triton X-100, sodium cholate, or sodium cholate/asolectin were indistinguishable from the value for native enzyme from brain homogenate. mipafox 0-7 patatin like phospholipase domain containing 6 Gallus gallus 75-78 3190748-2 1988 Assay of neuropathy target esterase (NTE) which accounts for about 70% of paraoxon-resistant phenyl valerate (PV) esterase activity of hen brain depends on the fact that it is selectively inhibited by mipafox. mipafox 201-208 patatin like phospholipase domain containing 6 Homo sapiens 9-35 3190748-2 1988 Assay of neuropathy target esterase (NTE) which accounts for about 70% of paraoxon-resistant phenyl valerate (PV) esterase activity of hen brain depends on the fact that it is selectively inhibited by mipafox. mipafox 201-208 patatin like phospholipase domain containing 6 Homo sapiens 37-40 3753463-8 1986 The fact that the Michaelis model fit the data significantly better than either of the other two models indicates that the higher apparent Ki values that occur with low concentrations of mipafox are due to formation of Michaelis complex at high concentrations, rather than because of the presence of two NTE isoenzymes, as has been suggested by other investigators. mipafox 187-194 patatin like phospholipase domain containing 6 Homo sapiens 304-307 3699331-7 1986 In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay. mipafox 64-71 patatin like phospholipase domain containing 6 Gallus gallus 84-87 3699331-7 1986 In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay. mipafox 64-71 patatin like phospholipase domain containing 6 Homo sapiens 84-87 3699331-7 1986 In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay. mipafox 64-71 patatin like phospholipase domain containing 6 Gallus gallus 84-87 3699331-7 1986 In conclusion, NTE from both species was very similar, with the mipafox I50 for rat NTE within the range of reported values for chicken and human NTE, and the inhibitor parameters of the chicken NTE assay were applicable for the rat NTE assay. mipafox 64-71 patatin like phospholipase domain containing 6 Gallus gallus 84-87 7278155-4 1981 Because of the commercial unavailability and high toxicity of mipafox, which is usually used as the selective inhibitor for assaying NTE, leptophosoxon was used as an alternative to mipafox. mipafox 62-69 patatin like phospholipase domain containing 6 Gallus gallus 133-136 6623525-2 1983 Enzyme activity from chick embryo brain with properties of neurotoxic esterase (NTE, insensitive to 40 microM paraoxon, sensitive to 50 microM mipafox) migrated in a 9S peak. mipafox 143-150 patatin like phospholipase domain containing 6 Gallus gallus 80-83 7078105-0 1982 A kinetic study on the inhibition of hen brain neurotoxic esterase by mipafox. mipafox 70-77 patatin like phospholipase domain containing 6 Homo sapiens 47-66 7078105-2 1982 The technique was used to determine the bimolecular rate (ki), phosphorylation (k2), and affinity (Kd) constants for the reaction of hen brain microsomal NTE with mipafox. mipafox 163-170 patatin like phospholipase domain containing 6 Homo sapiens 154-157 7078105-4 1982 The affinity and phosphorylation constants, Kd and k2, for the reaction of hen brain microsomal NTE with mipafox, were found to be 6.72 x 10(-5) M and 3.23 min-1, respectively. mipafox 105-112 patatin like phospholipase domain containing 6 Homo sapiens 96-99 7078105-4 1982 The affinity and phosphorylation constants, Kd and k2, for the reaction of hen brain microsomal NTE with mipafox, were found to be 6.72 x 10(-5) M and 3.23 min-1, respectively. mipafox 105-112 CD59 molecule (CD59 blood group) Homo sapiens 156-161 4049405-4 1985 We report here that paraoxon is apparently able to reduce the rate of inhibition of both neurotoxic esterase isozymes by mipafox in a concentration-dependent manner. mipafox 121-128 patatin like phospholipase domain containing 6 Homo sapiens 89-108 4049405-5 1985 As a result, the rate of inhibition of NTE by mipafox is greater when sequential, rather than concurrent, preinhibition is utilized. mipafox 46-53 patatin like phospholipase domain containing 6 Homo sapiens 39-42 7082366-3 1982 Included among the paraoxon-resistant esterases is neurotoxic esterase (NTE), which is inhibited in vivo and in vitro by certain organophosphorus compounds, such as mipafox, which cause delayed neurotoxicity. mipafox 165-172 patatin like phospholipase domain containing 6 Gallus gallus 51-70 7082366-3 1982 Included among the paraoxon-resistant esterases is neurotoxic esterase (NTE), which is inhibited in vivo and in vitro by certain organophosphorus compounds, such as mipafox, which cause delayed neurotoxicity. mipafox 165-172 patatin like phospholipase domain containing 6 Gallus gallus 72-75 7278155-5 1981 Results indicated that the NTE fraction of hen brain microsomal PV-hydrolyzing activity is the same target for either mipafox or leptophosoxon. mipafox 118-125 patatin like phospholipase domain containing 6 Gallus gallus 27-30 30088187-7 2019 Liraglutide protected cells against the neurotoxicity of mipafox by increasing neuritogenesis, the uptake of glucose, the levels of cytoskeleton proteins, and synaptic-plasticity modulators, besides decreasing the pro-inflammatory cytokine interleukin 1beta and caspase-3 activity. mipafox 57-64 interleukin 1 beta Homo sapiens 240-257 30088187-7 2019 Liraglutide protected cells against the neurotoxicity of mipafox by increasing neuritogenesis, the uptake of glucose, the levels of cytoskeleton proteins, and synaptic-plasticity modulators, besides decreasing the pro-inflammatory cytokine interleukin 1beta and caspase-3 activity. mipafox 57-64 caspase 3 Homo sapiens 262-271 26838044-0 2017 Butyrylcholinesterase identification in a phenylvalerate esterase-enriched fraction sensitive to low mipafox concentrations in chicken brain. mipafox 101-108 butyrylcholinesterase Gallus gallus 0-21 30176330-8 2018 Four enzymatic components (CP1, CP2, CP3 and CP4) were discriminated in cholinesterase activity in the membrane fraction according to their sensitivity to irreversible inhibitors mipafox, paraoxon, PMSF and iso-OMPA. mipafox 179-186 butyrylcholinesterase Gallus gallus 72-86 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 growth associated protein 43 Homo sapiens 121-127 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 synapsin I Homo sapiens 152-162 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 synaptophysin Homo sapiens 167-180 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 growth associated protein 43 Homo sapiens 292-298 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 synapsin I Homo sapiens 300-310 27939611-3 2017 Mipafox (20muM) decreased cellular differentiation and the expression of neurofilament 200 (NF-200), growth associated- (GAP-43) and synaptic proteins (synapsin I and synaptophysin); whereas paraoxon (300muM) induced no effect on cellular differentiation, but significant decrease of NF-200, GAP-43, synapsin I and synaptophysin as compared to controls. mipafox 0-7 synaptophysin Homo sapiens 315-328 28862523-6 2017 Only nimodipine inhibited reduction of synaptophysin levels produced by mipafox. mipafox 72-79 synaptophysin Homo sapiens 39-52 25743373-0 2016 Resolving pathways of interaction of mipafox and a sarin analog with human acetylcholinesterase by kinetics, mass spectrometry and molecular modeling approaches. mipafox 37-44 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-95 27117976-4 2016 We tested, in D3 mouse embryonic stem cells under differentiation, the effects of the NTE inhibition by the OPs mipafox, CPS and its main active metabolite chlorpyrifos-oxon (CPO) on the expression of genes Vegfa, Bcl2, Amot, Nes and Jun, previously reported to be under- or overexpressed after Pnpla6 silencing in this same cellular model. mipafox 112-119 patatin-like phospholipase domain containing 6 Mus musculus 86-89 27117976-5 2016 Mipafox did not significantly alter the expression of such genes at concentrations that significantly inhibited NTE. mipafox 0-7 patatin-like phospholipase domain containing 6 Mus musculus 112-115 27475862-7 2016 These phenotypic effects were not reproduced when NTE esterase activity was inhibited by neuropathic OP mipafox instead of being silenced at the genetic level. mipafox 104-111 patatin like phospholipase domain containing 6 Homo sapiens 50-53 27507601-3 2016 In this work, four enzymatic components (CS1, CS2, CS3 and CS4) of cholinesterase activity have been discriminated in soluble fraction, according to their sensitivity to irreversible inhibitors mipafox, paraoxon, PMSF and iso-OMPA and to reversible inhibitors ethopropazine and BW284C51. mipafox 194-201 butyrylcholinesterase Gallus gallus 67-81 25743373-5 2016 Here, our goal was to study oxime reactivation and aging reactions of human AChE inhibited by mipafox or a sarin analog (Flu-MPs, fluorescent methylphosphonate). mipafox 94-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 76-80 25596135-6 2015 Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE. mipafox 16-23 patatin like phospholipase domain containing 6 Homo sapiens 85-88 25910916-6 2015 Mipafox had the lowest IC50 and induced the highest percentage of aging of NTE among the OPs evaluated. mipafox 0-7 patatin like phospholipase domain containing 6 Homo sapiens 75-78 25910916-8 2015 Concentrations of mipafox and fenamiphos which inhibited at least 70% of NTE were also able to reduce neurite outgrowth. mipafox 18-25 patatin like phospholipase domain containing 6 Homo sapiens 73-76 25596135-6 2015 Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE. mipafox 16-23 patatin like phospholipase domain containing 6 Homo sapiens 115-118 25596135-6 2015 Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE. mipafox 16-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 124-128 19620706-3 2009 The activity of neuropathy target esterase is significantly inhibited by phenylmethylsulfonyl fluoride and paraoxon plus mipafox but not by paraoxon alone. mipafox 121-128 patatin-like phospholipase domain containing 6 Mus musculus 16-42 22503708-2 2012 In this work, we evaluate and characterize the interaction (inhibition, reactivation and "ongoing inhibition") of two model compounds: paraoxon (non-neuropathy-inducer) and mipafox (neuropathy-inducer), with esterases of chicken brain membranes, an animal model, tissue and fractions, where neuropathy target esterase (NTE) was first described and isolated. mipafox 173-180 patatin like phospholipase domain containing 6 Gallus gallus 291-317 22503708-2 2012 In this work, we evaluate and characterize the interaction (inhibition, reactivation and "ongoing inhibition") of two model compounds: paraoxon (non-neuropathy-inducer) and mipafox (neuropathy-inducer), with esterases of chicken brain membranes, an animal model, tissue and fractions, where neuropathy target esterase (NTE) was first described and isolated. mipafox 173-180 patatin like phospholipase domain containing 6 Gallus gallus 319-322 20603202-4 2010 Therefore, the present study was carried out to test the hypothesis that NTE in cultured skin fibroblasts from NTE-MND subjects also exhibit altered enzymological properties assessed by SA and IC(50) values of mipafox (MIP) and chlorpyrifos oxon (CPO). mipafox 210-217 patatin like phospholipase domain containing 6 Homo sapiens 73-76 20603202-4 2010 Therefore, the present study was carried out to test the hypothesis that NTE in cultured skin fibroblasts from NTE-MND subjects also exhibit altered enzymological properties assessed by SA and IC(50) values of mipafox (MIP) and chlorpyrifos oxon (CPO). mipafox 219-222 patatin like phospholipase domain containing 6 Homo sapiens 73-76 17913405-13 2007 The inhibition curve of mipafox on NTE activity of cNEST in mammalian cells was also reported here. mipafox 24-31 patatin like phospholipase domain containing 6 Homo sapiens 35-38 17323978-3 2007 However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP). mipafox 252-259 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 17663017-1 2007 Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate. mipafox 219-226 patatin like phospholipase domain containing 6 Homo sapiens 6-32 17663017-1 2007 Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate. mipafox 219-226 patatin like phospholipase domain containing 6 Homo sapiens 34-37 17323978-3 2007 However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP). mipafox 252-259 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-66 17323978-3 2007 However, recent evidence has shown that acetylcholinesterase (AChE) and the catalytic domain of human neuropathy target esterase (NEST) undergo aging by alternative mechanisms following their inhibition with N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP). mipafox 252-259 patatin like phospholipase domain containing 6 Homo sapiens 102-128 16963094-1 2007 Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase. mipafox 77-84 patatin-like phospholipase domain containing 6 Mus musculus 131-157 16963094-1 2007 Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase. mipafox 77-84 patatin-like phospholipase domain containing 6 Mus musculus 159-162 17207828-7 2007 When phenyl benzoate (PB) was used as substrate, about 65% of total activity was resistant to the non-promoter mipafox (up to 0.5 mM, 20 min, pH 8.0), that inhibits NTE and other esterases. mipafox 111-118 patatin like phospholipase domain containing 6 Homo sapiens 165-168 16963094-1 2007 Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase. mipafox 86-89 patatin-like phospholipase domain containing 6 Mus musculus 131-157 16963094-1 2007 Organophosphorus compounds (OP) such as phenyl saligenin phosphate (PSP) and mipafox (MPX) which cause delayed neuropathy, inhibit neuropathy target esterase (NTE), while OPs such as paraoxon (PXN) react more readily with acetylcholinesterase. mipafox 86-89 patatin-like phospholipase domain containing 6 Mus musculus 159-162 16963094-4 2007 In cortical and cerebellar granule neurons and astrocytes, [(14)C]GroPCho labeling was inhibited by PSP and MPX: phenyl dipentylphosphinate (PDPP), a non-neuropathic NTE inhibitor, was more potent, while PXN, was substantially less so. mipafox 108-111 patatin-like phospholipase domain containing 6 Mus musculus 166-169 17184757-6 2007 Immediately after mipafox treatment NTE activity represented 3% of the control (6.7+/-1.9mU/10(6) cells). mipafox 18-25 patatin like phospholipase domain containing 6 Bos taurus 36-39 17184757-0 2007 Recovery of neuropathy target esterase activity after inhibition with mipafox and O-hexyl O-2,5-dichlorophenyl phosphoramidate in bovine chromaffin cell cultures. mipafox 70-77 patatin like phospholipase domain containing 6 Bos taurus 12-38 16122834-6 2005 Mipafox, a neurotoxic organophosphate, was shown to block process outgrowth and differentiation in cells that have lowered NTE activity due to RNA interference, suggesting that mipafox may interact with other molecules to exert its effect in this context. mipafox 0-7 patatin like phospholipase domain containing 6 Homo sapiens 123-126 16766477-5 2006 The anti-AChE activity of paraoxon (maximum 3 muM) and anti-NTE activity of mipafox (250 muM) in SY5Y cells were prevented by biodegradation with OPH. mipafox 76-83 patatin like phospholipase domain containing 6 Homo sapiens 60-63 16766477-5 2006 The anti-AChE activity of paraoxon (maximum 3 muM) and anti-NTE activity of mipafox (250 muM) in SY5Y cells were prevented by biodegradation with OPH. mipafox 76-83 acylaminoacyl-peptide hydrolase Homo sapiens 146-149 16766477-6 2006 Anti-AChE activities of mipafox, methyl parathion, and demeton-S were partially ameliorated, depending on OP concentration. mipafox 24-31 acetylcholinesterase (Cartwright blood group) Homo sapiens 5-9 16766477-8 2006 However, NF200 levels rose in cells treated during late differentiation with OPH-treated mipafox. mipafox 89-96 acylaminoacyl-peptide hydrolase Homo sapiens 77-80 16485911-0 2006 Aging of mipafox-inhibited human acetylcholinesterase proceeds by displacement of both isopropylamine groups to yield a phosphate adduct. mipafox 9-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-53 16485911-3 2006 Recently, however, it has been shown that the catalytic domain of human NTE inhibited by N,N"-diisopropylphosphorodiamidofluoridate (mipafox, MIP) ages by deprotonation. mipafox 133-140 patatin like phospholipase domain containing 6 Homo sapiens 72-75 16122834-6 2005 Mipafox, a neurotoxic organophosphate, was shown to block process outgrowth and differentiation in cells that have lowered NTE activity due to RNA interference, suggesting that mipafox may interact with other molecules to exert its effect in this context. mipafox 177-184 patatin like phospholipase domain containing 6 Homo sapiens 123-126 15205030-3 2004 Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A). mipafox 0-7 nerve growth factor Homo sapiens 117-141 15205030-3 2004 Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A). mipafox 0-7 nerve growth factor Homo sapiens 143-146 15205030-3 2004 Mipafox, which induces OPIDN, increased NF200 protein expression in SY5Y cells differentiated with human recombinant beta-nerve growth factor (NGF, 20 ng/ml) in a concentration-dependent manner, compared to NGF controls, when SY5Y cells were exposed to 0.3 or 30 microM mipafox during the last 5 days of neurite extension (experimental set A). mipafox 0-7 nerve growth factor Homo sapiens 207-210 15177651-2 2004 Organophosphorus-induced polyneuropathy is a syndrome related to the inhibition and further modification by organophosphorus compounds of NTE (a protein that displays phenyl valerate esterase activity resistant to mipafox and sensitive to paraoxon). mipafox 214-221 patatin like phospholipase domain containing 6 Bos taurus 138-141 15177651-8 2004 We conclude that NTE could be assayed in this system by only using one inhibitor (mipafox) instead of two (paraoxon and mipafox). mipafox 82-89 patatin like phospholipase domain containing 6 Bos taurus 17-20 15177651-8 2004 We conclude that NTE could be assayed in this system by only using one inhibitor (mipafox) instead of two (paraoxon and mipafox). mipafox 120-127 patatin like phospholipase domain containing 6 Bos taurus 17-20 15177652-10 2004 The model equation with a fixed AR value was again applied (step 3) to deduce the second-order inhibition rate constants (k1=2.6 x 10(6) M-1 min-1 and k2=0.28 x 10(6) M-1 min-1), being conserved consistently throughout all mipafox concentrations. mipafox 223-230 myoregulin Homo sapiens 137-146 15052610-6 2004 Cholinesterase activities (with acetylthiocholine [ChE-A] and butyrylthiocholine [ChE-B] as substrates) in human plasma were measured photometrically in the presence of different MPFX concentrations and the IC(50) was calculated. mipafox 179-183 butyrylcholinesterase Homo sapiens 0-14 15035642-0 2004 The mipafox-inhibited catalytic domain of human neuropathy target esterase ages by reversible proton loss. mipafox 4-11 patatin like phospholipase domain containing 6 Homo sapiens 48-74 15035642-3 2004 N,N"-Diisopropylphosphorodiamidofluoridate (mipafox, MIP)-inhibited NTE has been thought to age quickly; however, it can be reactivated under acidic conditions. mipafox 44-51 major intrinsic protein of lens fiber Homo sapiens 53-56 15035642-3 2004 N,N"-Diisopropylphosphorodiamidofluoridate (mipafox, MIP)-inhibited NTE has been thought to age quickly; however, it can be reactivated under acidic conditions. mipafox 44-51 patatin like phospholipase domain containing 6 Homo sapiens 68-71